Journal article
Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.
Abstract
390 Background: Patients treated with immune checkpoint blockade (ICB) may experience disease control without need for ongoing systemic therapy, a period not well described by conventional time-to-event endpoints. Treatment-free survival (TFS) represents a novel endpoint to quantify this period. Methods: We identified patients with mRCC from the IMDC dataset initiating first-line systemic therapy with VEGFR monotherapy (sunitinib, pazopanib), …
Authors
Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura KN
Journal
Journal of Clinical Oncology, Vol. 42, No. 4_suppl, pp. 390–390
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2024
DOI
10.1200/jco.2024.42.4_suppl.390
ISSN
0732-183X